Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years

P. Klener, E. Fronkova, A. Berkova, R. Jaksa, H. Lhotska, K. Forsterova, J. Soukup, V. Kulvait, J. Vargova, K. Fiser, D. Prukova, M. Alam, B. Calvin Lenyeletse Maswabi, K. Michalova, Z. Zemanova, T. Jancuskova, S. Pekova, M. Trneny,

. 2016 ; 139 (10) : 2252-60. [pub] 20160802

Language English Country United States

Document type Case Reports, Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023854

Grant support
NV15-27757A MZ0 CEP Register

Richter syndrome represents the transformation of the chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most frequently the diffuse large B-cell lymphoma (DLBCL). In this report we describe a patient with CLL, who developed a clonally-related pleomorphic highly-aggressive mantle cell lymphoma (MCL) after five cycles of a fludarabine-based second-line therapy for the first relapse of CLL. Molecular cytogenetic methods together with whole-exome sequencing revealed numerous gene alterations restricted to the MCL clone (apart from the canonical t(11;14)(q13;q32) translocation) including gain of one copy of ATM gene or emergence of TP53, CREBBP, NUP214, FUBP1 and SF3B1 gene mutations. Similarly, gene expression analysis revealed vast differences between the MCL and CLL transcriptome, including overexpression of cyclin D1, downregulation of cyclins D2 and D3, or downregulation of IL4R in the MCL clone. Backtracking analysis using quantitative PCR specifically detecting an MCL-restricted focal deletion of TP53 revealed that the pre-MCL clone appeared in the bone marrow and peripheral blood of the patient approximately 4 years before the clinical manifestation of MCL. Both molecular cytogenetic and sequencing data support the hypothesis of a slow development of the pre-MCL clone in parallel to CLL over several years, and thereby exclude the possibility that the transformation event occurred at the stage of the CLL relapse clone by mere t(11;14)(q13;q32) acquisition.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023854
003      
CZ-PrNML
005      
20250225094758.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.30263 $2 doi
035    __
$a (PubMed)27407063
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klener, Pavel $u Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic. pavel.klener@gmail.com. Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. pavel.klener@gmail.com.
245    10
$a Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years / $c P. Klener, E. Fronkova, A. Berkova, R. Jaksa, H. Lhotska, K. Forsterova, J. Soukup, V. Kulvait, J. Vargova, K. Fiser, D. Prukova, M. Alam, B. Calvin Lenyeletse Maswabi, K. Michalova, Z. Zemanova, T. Jancuskova, S. Pekova, M. Trneny,
520    9_
$a Richter syndrome represents the transformation of the chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most frequently the diffuse large B-cell lymphoma (DLBCL). In this report we describe a patient with CLL, who developed a clonally-related pleomorphic highly-aggressive mantle cell lymphoma (MCL) after five cycles of a fludarabine-based second-line therapy for the first relapse of CLL. Molecular cytogenetic methods together with whole-exome sequencing revealed numerous gene alterations restricted to the MCL clone (apart from the canonical t(11;14)(q13;q32) translocation) including gain of one copy of ATM gene or emergence of TP53, CREBBP, NUP214, FUBP1 and SF3B1 gene mutations. Similarly, gene expression analysis revealed vast differences between the MCL and CLL transcriptome, including overexpression of cyclin D1, downregulation of cyclins D2 and D3, or downregulation of IL4R in the MCL clone. Backtracking analysis using quantitative PCR specifically detecting an MCL-restricted focal deletion of TP53 revealed that the pre-MCL clone appeared in the bone marrow and peripheral blood of the patient approximately 4 years before the clinical manifestation of MCL. Both molecular cytogenetic and sequencing data support the hypothesis of a slow development of the pre-MCL clone in parallel to CLL over several years, and thereby exclude the possibility that the transformation event occurred at the stage of the CLL relapse clone by mere t(11;14)(q13;q32) acquisition.
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a lidské chromozomy, pár 11 $7 D002880
650    _2
$a lidské chromozomy, pár 14 $7 D002883
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a chronická lymfatická leukemie $x genetika $x metabolismus $x patologie $7 D015451
650    _2
$a ztráta heterozygozity $7 D019656
650    _2
$a difúzní velkobuněčný B-lymfom $x genetika $x metabolismus $x patologie $7 D016403
650    _2
$a lymfom z plášťových buněk $x genetika $x metabolismus $x patologie $7 D020522
650    _2
$a lidé středního věku $7 D008875
650    _2
$a translokace genetická $7 D014178
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fronkova, Eva $u Childhood Leukemia Investigation Prague (CLIP), Faculty Hospital Motol Prague, Prague, Czech Republic.
700    1_
$a Berková, Adéla $u Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0325890
700    1_
$a Jaksa, Radek $u Department of Pathology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Lhotska, Halka $u Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Forsterova, Kristina $u Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Soukup, Jan, $d 1963- $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Faculty Hospital Motol Prague, Prague, Czech Republic. $7 xx0140786
700    1_
$a Kulvait, Vojtech $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Vargova, Jarmila $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Fiser, Karel $u Childhood Leukemia Investigation Prague (CLIP), Faculty Hospital Motol Prague, Prague, Czech Republic.
700    1_
$a Prukova, Dana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Alam, Mahmudul $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 gn_A_00003252
700    1_
$a Calvin Lenyeletse Maswabi, Bokang $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Michalova, Kyra $u Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Zemanova, Zuzana $u Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Jancuskova, Tereza $u Synlab Genetics, Department of Cytogenetics, Prague, Czech Republic.
700    1_
$a Pekova, Sona $u Synlab Genetics, Department of Cytogenetics, Prague, Czech Republic.
700    1_
$a Trneny, Marek $u Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 139, č. 10 (2016), s. 2252-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27407063 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20250225094755 $b ABA008
999    __
$a ok $b bmc $g 1239535 $s 984767
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 139 $c 10 $d 2252-60 $e 20160802 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a NV15-27757A $p MZ0
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options